Pharmaceutical sector sees flurry of acquisitions

September 2013
Chain Drug Review;9/9/2013, Vol. 35 Issue 14, p13
Trade Publication
The article offers information on several acquisitions in the U.S. pharmaceutical industry including the purchase of Onyx Pharmaceuticals Inc. by Amgen Inc., acquisition of Hi-Tech Pharmacal Co. by Akorn Inc. and purchase of Amplimmune Inc. by AstraZeneca PLC.


Related Articles

  • Onyx Pharmaceuticals to acquire Proteolix.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p33 

    The article reports on the signed definitive agreement to acquire biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. It notes that Proteolix is set to be paid 276 million dollars upon finalization of the transaction in the fourth quarter of 2009. It mentions that Proteolix is...

  • Onyx Pharmaceuticals completes acquisition of Proteolix.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p26 

    The article reports on the acquisition of the biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. for the development of medical therapies against hematological tumors. According to Onyx chief executive officer (CEO), Anthony Coles, the acquisition places the firm as a...

  • WEEK IN REVIEW.  // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p6 

    The article presents financings and deals of pharmaceutical companies. Adventrx Pharmaceuticals Inc. received a gross income of 11.3 million dollars from its registered direct offering of stock and warrants. Allos Therapeutics Inc. obtained on its disclosed public stock offering a net income of...

  • WEEK IN REVIEW.  // BioWorld Insight;2/15/2010, Vol. 18 Issue 7, p5 

    The article lists the finance and deals engaged by several pharmaceutical firms like the 25 million U.S. dollar million credit facility secured by EUSA Pharma Inc., the 130 million U.S. dollar deal between Alexza Pharmaceuticals Inc. with Biovail Laboratories International SRL, and the...

  • Precious Mettle. Comer, Benjamin // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28 

    The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds,...

  • EARNINGS ROUNDUP.  // BioWorld Today;5/8/2008, Vol. 19 Issue 90, p2 

    This section offers news briefs concerning the U.S. biopharmaceutical industry. Emergent BioSolutions, Inc. has posted increased revenues and a net income of $7 million or 24 cents per share for the first quarter of 2008. The total sales generated by Onyx Pharmaceuticals, Inc. for its Nexavar...

  • COMPANY SPOTLIGHT - Onyx Pharmaceuticals, Inc.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p24 

    The article presents a company profile for Onyx Pharmaceuticals Inc., a U.S.-based biopharmaceutical company engaged in research and development of drugs for cancer treatment. Nexavar or sorafenib, a kinase and angiogenesis inhibitor for targeting signal pathways for the proliferation of cancer...

  • TURBULENT WATERS. Young, Peter // Pharmaceutical Representative;Dec2011, Vol. 41 Issue 12, p12 

    The article focuses on the continued merger and acquisition in the pharmaceutical industry in the U.S. It notes that merger and acquisitions by pharmaceutical companies has continued and became stronger from 2010 to the first half of 2011. Such development was driven by companies' goals to fill...

  • Update.  // Medical Marketing & Media;Nov2012, Vol. 47 Issue 11, p21 

    The article offers news briefs in the U.S. pharmaceutical industry including Targacept Inc.'s move to layoff 65 employees, the deal between Plavix and Avapro, and Merck's plan to move its office from Whitehouse Station to Summit, New Jersey.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics